Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- 17 May 2012
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 119 (20), 4597-4607
- https://doi.org/10.1182/blood-2011-10-388298
Abstract
Mantle cell lymphoma (MCL) carries an unfavorable prognosis and requires new treatment strategies. The associated t(11:14) translocation results in enhanced cyclin D1 expression and cyclin D1–dependent kinase activity to promote cell-cycle progression. A pharmacodynamic study of the selective CDK4/6 inhibitor PD0332991 was conducted in 17 patients with relapsed disease, using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) and 3-deoxy-3[18F]fluorothymidine (FLT) positron emission tomography (PET) to study tumor metabolism and proliferation, respectively, in concert with pre- and on-treatment lymph node biopsies to assess retinoblastoma protein (Rb) phosphorylation and markers of proliferation and apoptosis. Substantial reductions in the summed FLT-PET maximal standard uptake value (SUVmax), as well as in Rb phosphorylation and Ki-67 expression, occurred after 3 weeks in most patients, with significant correlations among these end points. Five patients achieved progression-free survival time of > 1 year (range, 14.9-30.1+ months), with 1 complete and 2 partial responses (18% objective response rate; 90% confidence interval, 5%-40%). These patients demonstrated > 70%, > 90%, and ≥ 87.5% reductions in summed FLT SUVmax and expression of phospho-Rb and Ki67, respectively, parameters necessary but not sufficient for long-term disease control. The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. This study is registered at www.clinicaltrials.gov under identifier NCT00420056.Keywords
This publication has 43 references indexed in Scilit:
- A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell LymphomaJournal of Nuclear Medicine, 2011
- Mantle cell lymphoma: The promise of new treatment optionsCritical Reviews in Oncology/Hematology, 2011
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)British Journal of Cancer, 2011
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood, 2011
- Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell LineCancer Research, 2010
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung CarcinomaCancer Cell, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Imaging of Cell Proliferation: Status and ProspectsJournal of Nuclear Medicine, 2008
- Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activityBlood, 2006
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal Of Cancer, 1999